Marker Therapeutics (MRKR) Operating Margin (2016 - 2025)
Marker Therapeutics (MRKR) reported Operating Margin of 765.68% for Q4 2025, up 54302.0% year-over-year from N/an in Q4 2024, and up 541.82% quarter-over-quarter from 173.3% in Q3 2025.
Marker Therapeutics (MRKR) Operating Margin (2016 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has 9 years of Operating Margin data on file, last reported at 765.68% in Q4 2025.
- Operating Margin for Q4 2025 came in at 765.68%, up 54302.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 81.95% (down 5173.0% YoY), and the FY2025 annual result was 72.11%, down 3808.0% from the prior year.
- Operating Margin improved to 765.68% in Q4 2025 per MRKR's latest filing, from 173.3% in the prior quarter.
- Over five years, Operating Margin peaked at 1659.68% in Q4 2022 and troughed at 1420.14% in Q1 2025.
- A 4-year average of 188.81% and a median of 189.1% in 2024 frame the typical range for Operating Margin.
- On a YoY basis, Operating Margin climbed as much as 148835 bps in 2023 and fell as far as 193774 bps in 2023.
- A 4-year view of Operating Margin shows it stood at 1659.68% in 2022, then slumped by 117 bps to 278.06% in 2023, then jumped by 180 bps to 222.66% in 2024, then surged by 244 bps to 765.68% in 2025.
- Business Quant data shows MRKR's Operating Margin at 765.68% in Q4 2025, 173.3% in Q3 2025, and 494.79% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 27.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 765.68% |
| Sep 30, 2025 | -173.30% |
| Jun 30, 2025 | -494.79% |
| Mar 31, 2025 | -1,420.14% |
| Dec 31, 2024 | 222.66% |
| Sep 30, 2024 | -124.60% |
| Jun 30, 2024 | -115.40% |
| Mar 31, 2024 | -204.89% |
| Dec 31, 2023 | -278.06% |
| Sep 30, 2023 | -1,242.22% |
| Jun 30, 2023 | 821.87% |
| Mar 31, 2023 | -172.38% |
| Dec 31, 2022 | 1,659.68% |
| Sep 30, 2022 | -582.90% |
| Jun 30, 2022 | -666.47% |
| Mar 31, 2022 | -1,015.71% |
| Jun 30, 2020 | -1,361.99% |
| Dec 31, 2019 | -2,681.02% |
| Jun 30, 2018 | -2,268.90% |
| Sep 30, 2017 | -2,179.30% |